

March 4, 2026



# Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

*~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~*

**SAN DIEGO, CALIFORNIA / [ACCESS Newswire](#) / March 4, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)** ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the successful initiation of its live "Ask Me Anything" (AMA) series on March 4, 2024. The event reinforced the Company's commitment to transparency, accessibility, and open dialogue with its community. A replay of the AMA series is available on the Company's website [here](#).

The AMA provided Ensysce shareholders and followers with the opportunity to engage directly with Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, covering topics such as Phase 3 execution and timeline visibility, capital discipline and shareholder alignment, as well as strategic priorities and long-term value creation. The event generated numerous distinct questions, arranged under 3 topics reflecting strong engagement and interest from the community.

"Our recent AMA session provided an important opportunity to engage directly with stakeholders and reinforce the strategic clarity behind our PF614 program," said Dr. Kirkpatrick. "We believe there is significant commercial potential for PF614 and that we are positioning the program to address unmet needs in the marketplace. We remain focused on disciplined execution and transparent communication as we advance these programs toward meaningful milestones."

Key highlights from the AMA included:

- PF614-301 timeline sequencing
- Efforts to reduce clinical and regulatory uncertainty
- PF614, PF614-MPAR & ADHD pipeline prioritization
- Potential PF614 commercial opportunities

For those who were unable to have their questions answered, please reach out for future opportunities to investor relations at [ENSC@mzgroup.us](mailto:ENSC@mzgroup.us).

**About Ensysce Biosciences**

Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit [www.ensysce.com](http://www.ensysce.com).

## **Forward-Looking Statements**

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at [www.sec.gov](http://www.sec.gov). Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

## **Ensysce Biosciences Company Contact:**

Lynn Kirkpatrick, Ph.D.  
Chief Executive Officer  
(858) 263-4196

## **Ensysce Biosciences Investor Relations Contact:**

Shannon Devine

MZ North America  
Main: 203-741-8811  
[ENSC@mzgroup.us](mailto:ENSC@mzgroup.us)

**SOURCE:** Ensysce Biosciences

View the original [press release](#) on ACCESS Newswire